EE200200589A - 8ß-hüdrokarbüülasendatud östratrieenid kasutamiseks selektiivsete östrogeenidena - Google Patents

8ß-hüdrokarbüülasendatud östratrieenid kasutamiseks selektiivsete östrogeenidena

Info

Publication number: EE200200589A
Authority: EE; Estonia
Prior art keywords: sup; compounds; action; 8beta; 5ht2a
Prior art date: 2000-04-12

Application number

EEP200200589A

Other languages

English (en)

Estonian (et)

Inventor

Peters Olaf

Hillisch Alexander

Thieme Ina

Elger Walter

Hegele-Hartung Christa

Kollenkirchen Uwe

Fritzemeier Karl-Heinrich

Patchev Vladimir

Original Assignee

Schering Aktiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-12

Filing date

2001-04-12

Publication date

2004-04-15

2000-04-12 Priority claimed from DE10019167A external-priority patent/DE10019167A1/de

2001-04-12 Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft

2004-04-15 Publication of EE200200589A publication Critical patent/EE200200589A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0062—Estrane derivatives substituted in position 17 alfa not substituted in position 17 beta
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0074—Esters
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Gynecology & Obstetrics (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Toxicology (AREA)
Pregnancy & Childbirth (AREA)
Pulmonology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EEP200200589A 2000-04-12 2001-04-12 8ß-hüdrokarbüülasendatud östratrieenid kasutamiseks selektiivsete östrogeenidena EE200200589A (et)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE10019167A DE10019167A1 (de)	2000-04-12	2000-04-12	Substituierte Estratriene als selektiv wirksame Estrogene
US20737000P	2000-05-26	2000-05-26
PCT/EP2001/004290 WO2001077139A1 (de)	2000-04-12	2001-04-12	8.beta.-hydrocarbyl-substituierte estratriene als selektiv wirksame estrogene

Publications (1)

Publication Number	Publication Date
EE200200589A true EE200200589A (et)	2004-04-15

Family

ID=26005365

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200200589A EE200200589A (et)	2000-04-12	2001-04-12	8ß-hüdrokarbüülasendatud östratrieenid kasutamiseks selektiivsete östrogeenidena

Country Status (25)

Country	Link
US (3)	US7378404B2 (xx)
EP (2)	EP1272504B1 (xx)
JP (2)	JP3828423B2 (xx)
CN (1)	CN100453549C (xx)
AT (2)	ATE302790T1 (xx)
AU (3)	AU2001258341B2 (xx)
BG (1)	BG107173A (xx)
BR (1)	BR0109983A (xx)
CA (1)	CA2406177C (xx)
CZ (1)	CZ20023382A3 (xx)
DE (1)	DE50112561D1 (xx)
DK (2)	DK1272504T3 (xx)
EA (1)	EA006299B1 (xx)
EE (1)	EE200200589A (xx)
ES (2)	ES2245694T3 (xx)
HR (1)	HRP20020892B1 (xx)
HU (1)	HUP0300335A2 (xx)
IL (2)	IL152248A0 (xx)
MX (1)	MXPA02010066A (xx)
NO (2)	NO325337B1 (xx)
NZ (1)	NZ543724A (xx)
PL (1)	PL207488B1 (xx)
PT (1)	PT1272504E (xx)
SK (1)	SK14632002A3 (xx)
WO (2)	WO2001077138A1 (xx)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1272504B1 (de) *	2000-04-12	2007-05-30	Bayer Schering Pharma Aktiengesellschaft	8.beta.-hydrocarbyl-substituierte estratriene als selektiv wirksame estrogene
DE10027887A1 (de)	2000-05-31	2001-12-13	Jenapharm Gmbh	Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE10039199A1 (de) *	2000-08-10	2002-02-21	Schering Ag	Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
GB0020498D0 (en)	2000-08-18	2000-10-11	Sterix Ltd	Compound
DE10151363A1 (de) *	2001-10-17	2003-05-08	Schering Ag	Somatotrope Therapie
DE10226326A1 (de) *	2002-06-11	2004-01-15	Schering Ag	9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene
ATE410170T1 (de) *	2003-03-27	2008-10-15	Pantarhei Bioscience Bv	Verwendung von estrogenen zur behandlung von männerunfruchtbarkeit
DE10318896A1 (de) *	2003-04-22	2004-11-25	Schering Ag	8beta-Vinyl-11beta-(omega-substituierte)alkyl-estra-1,3,5(10)-triene
PL1689410T3 (pl) *	2003-11-26	2008-10-31	Bayer Schering Pharma Ag	Sposób zapobiegania i leczenia nadciśnieniowych chorób serca za pomocą selektywnych estrogenów: 8ß-winylo-estra-1,3,5(10)-trien-3,17ß-diolu i 17ß-fluoro-9a-winylo-estra-1,3,5(10)-trien-3,16a-diolu
US7534780B2 (en)	2004-05-21	2009-05-19	Bayer Schering Pharma Aktiengesellschaft	Estradiol prodrugs
DE102005057225A1 (de) *	2005-11-29	2007-05-31	Bayer Schering Pharma Ag	Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE102005057224A1 (de) *	2005-11-29	2007-05-31	Bayer Schering Pharma Ag	Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP2014672A1 (en) *	2007-07-12	2009-01-14	Bayer Schering Pharma Aktiengesellschaft	8-beta-substituted estratrienes as selectively active estrogens
MX2010008940A (es) *	2008-02-13	2010-10-05	Bayer Schering Pharma Ag	Sistemas de administracion de drogas que contienen estradiol.
WO2009100871A2 (en) *	2008-02-13	2009-08-20	Bayer Schering Pharma Aktiengesellschaft	Drug delivery system with stabilising effect
EP2143432A1 (en)	2008-07-11	2010-01-13	Bayer Schering Pharma AG	9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer
WO2010057594A1 (en) *	2008-11-21	2010-05-27	Bayer Schering Pharma Aktiengesellschaft	Drug delivery system
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
ES2885523T3 (es)	2011-11-23	2021-12-14	Therapeuticsmd Inc	Formulaciones y terapias de reposición hormonal de combinación naturales
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es)	2014-05-22	2016-10-12	Therapeuticsmd Inc	Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
CA3020153A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical composition
WO2017173044A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd Inc.	Steroid hormone compositions in medium chain oils
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2743E (fr) *	1902-01-11	1904-12-15	Adolphe Ernest Pointe	Panification augmentant le rendement et la digestibilité
JPS454059Y1 (xx) *	1967-11-04	1970-02-25
JPS454060Y1 (xx) *	1967-12-11	1970-02-25
US3501530A (en) *	1968-02-27	1970-03-17	American Cyanamid Co	Substituted naphthalenones,naphthalenediones and d-homo - beta - nor estra-1,3,5(10),9(11)-tetraenes
US3806546A (en) *	1969-06-18	1974-04-23	American Cyanamid Co	Steroid-like compounds and method of synthesis
US3681407A (en) *	1969-06-18	1972-08-01	American Cyanamid Co	3-methoxy 8{62 -methylestra 1,3,5(10),9(11)-tetraene-17{62 -carboxylic acid lower alkyl ester and intermediates in the preparation thereof
US3709878A (en) *	1970-07-20	1973-01-09	Sandoz Ag	8 alpha-methyl-substituted-steroids
US3736345A (en) *	1971-05-18	1973-05-29	American Cyanamid Co	Steroid-like compounds and method of synthesis
US4961931A (en) *	1982-07-29	1990-10-09	Alza Corporation	Method for the management of hyperplasia
DE4018828C2 (de) *	1989-06-08	1999-05-12	Schering Ag	Verfahren zur Herstellung C7-alpha-substituierter 8alpha- und 8ß-Estra-1,3,5(10)-triene und C8-alpha-substituierter Estra-1,3,5(10)-triene sowie neue Zwischenprodukte für dieses Verfahren
AU710139B2 (en) *	1996-05-01	1999-09-16	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	21-substituted progesterone derivatives as new antiprogestational agents
WO2000031112A1 (en) *	1998-11-20	2000-06-02	Akzo Nobel N.V.	Estrogenic estra-1,3,5(10)-trienes with differential effects on the alpha and beta estrogen receptors, having a linear hydrocarbon chain of from 5-9 carbon atoms in position 11
EP1272504B1 (de) *	2000-04-12	2007-05-30	Bayer Schering Pharma Aktiengesellschaft	8.beta.-hydrocarbyl-substituierte estratriene als selektiv wirksame estrogene
DE10019167A1 (de) *	2000-04-12	2001-10-18	Schering Ag	Substituierte Estratriene als selektiv wirksame Estrogene
DE10318896A1 (de) *	2003-04-22	2004-11-25	Schering Ag	8beta-Vinyl-11beta-(omega-substituierte)alkyl-estra-1,3,5(10)-triene

2001
- 2001-04-12 EP EP01931609A patent/EP1272504B1/de not_active Expired - Lifetime
- 2001-04-12 BR BR0109983-3A patent/BR0109983A/pt not_active IP Right Cessation
- 2001-04-12 PT PT01931609T patent/PT1272504E/pt unknown
- 2001-04-12 DK DK01931609T patent/DK1272504T3/da active
- 2001-04-12 CZ CZ20023382A patent/CZ20023382A3/cs unknown
- 2001-04-12 JP JP2001575608A patent/JP3828423B2/ja not_active Expired - Lifetime
- 2001-04-12 NZ NZ543724A patent/NZ543724A/en unknown
- 2001-04-12 CA CA2406177A patent/CA2406177C/en not_active Expired - Fee Related
- 2001-04-12 DE DE50112561T patent/DE50112561D1/de not_active Expired - Lifetime
- 2001-04-12 PL PL358667A patent/PL207488B1/pl not_active IP Right Cessation
- 2001-04-12 US US10/257,288 patent/US7378404B2/en not_active Expired - Fee Related
- 2001-04-12 ES ES01940331T patent/ES2245694T3/es not_active Expired - Lifetime
- 2001-04-12 HR HR20020892A patent/HRP20020892B1/xx not_active IP Right Cessation
- 2001-04-12 EE EEP200200589A patent/EE200200589A/xx unknown
- 2001-04-12 AT AT01940331T patent/ATE302790T1/de not_active IP Right Cessation
- 2001-04-12 US US10/257,287 patent/US20040029847A1/en not_active Abandoned
- 2001-04-12 SK SK1463-2002A patent/SK14632002A3/sk unknown
- 2001-04-12 IL IL15224801A patent/IL152248A0/xx active IP Right Grant
- 2001-04-12 EP EP01940331A patent/EP1272505B1/de not_active Expired - Lifetime
- 2001-04-12 EA EA200201052A patent/EA006299B1/ru not_active IP Right Cessation
- 2001-04-12 WO PCT/EP2001/004289 patent/WO2001077138A1/de not_active Ceased
- 2001-04-12 AU AU2001258341A patent/AU2001258341B2/en not_active Ceased
- 2001-04-12 DK DK01940331T patent/DK1272505T3/da active
- 2001-04-12 CN CNB018107745A patent/CN100453549C/zh not_active Expired - Fee Related
- 2001-04-12 AU AU5834101A patent/AU5834101A/xx active Pending
- 2001-04-12 HU HU0300335A patent/HUP0300335A2/hu unknown
- 2001-04-12 WO PCT/EP2001/004290 patent/WO2001077139A1/de not_active Ceased
- 2001-04-12 AT AT01931609T patent/ATE363487T1/de active
- 2001-04-12 ES ES01931609T patent/ES2287127T3/es not_active Expired - Lifetime
- 2001-04-12 AU AU2001273945A patent/AU2001273945A1/en not_active Abandoned
- 2001-04-12 MX MXPA02010066A patent/MXPA02010066A/es active IP Right Grant
2002
- 2002-10-08 BG BG107173A patent/BG107173A/bg unknown
- 2002-10-10 IL IL152248A patent/IL152248A/en not_active IP Right Cessation
- 2002-10-11 NO NO20024908A patent/NO325337B1/no unknown
- 2002-10-11 NO NO20024907A patent/NO20024907L/no not_active Application Discontinuation
2008
- 2008-03-11 US US12/045,979 patent/US20080182829A1/en not_active Abandoned
- 2008-06-25 JP JP2008166585A patent/JP2008280355A/ja active Pending

Also Published As

Publication number	Publication date
NZ543724A (en)	2007-07-27
JP3828423B2 (ja)	2006-10-04
JP2003530403A (ja)	2003-10-14
ES2245694T3 (es)	2006-01-16
CA2406177A1 (en)	2001-10-18
EP1272504A1 (de)	2003-01-08
ATE363487T1 (de)	2007-06-15
PL207488B1 (pl)	2010-12-31
NO20024907L (no)	2002-12-05
US7378404B2 (en)	2008-05-27
NO20024907D0 (no)	2002-10-11
CN1433424A (zh)	2003-07-30
HRP20020892A2 (en)	2005-02-28
HK1057219A1 (zh)	2004-03-19
IL152248A0 (en)	2003-05-29
HUP0300335A2 (hu)	2003-07-28
WO2001077139A1 (de)	2001-10-18
EP1272505A1 (de)	2003-01-08
AU2001258341B2 (en)	2007-03-15
EP1272505B1 (de)	2005-08-24
MXPA02010066A (es)	2003-06-04
HRP20020892B1 (en)	2011-08-31
CZ20023382A3 (cs)	2003-02-12
AU5834101A (en)	2001-10-23
NO20024908L (no)	2002-11-13
EA200201052A1 (ru)	2003-04-24
IL152248A (en)	2008-06-05
SK14632002A3 (sk)	2003-03-04
BR0109983A (pt)	2003-02-25
DK1272505T3 (da)	2005-11-07
EP1272504B1 (de)	2007-05-30
US20040029847A1 (en)	2004-02-12
PT1272504E (pt)	2007-08-29
US20080182829A1 (en)	2008-07-31
EA006299B1 (ru)	2005-10-27
AU2001273945A1 (en)	2001-10-23
DE50112561D1 (de)	2007-07-12
CN100453549C (zh)	2009-01-21
WO2001077138A1 (de)	2001-10-18
CA2406177C (en)	2010-06-22
DK1272504T3 (da)	2007-10-01
PL358667A1 (en)	2004-08-09
NO325337B1 (no)	2008-03-31
JP2008280355A (ja)	2008-11-20
US20030176405A1 (en)	2003-09-18
BG107173A (bg)	2003-05-30
NO20024908D0 (no)	2002-10-11
ATE302790T1 (de)	2005-09-15
ES2287127T3 (es)	2007-12-16

Publication	Publication Date	Title
EE200200589A (et)	2004-04-15	8ß-hüdrokarbüülasendatud östratrieenid kasutamiseks selektiivsete östrogeenidena
CN1057305C (zh)	2000-10-11	雌－1,3,5(10)－三烯衍生物,其制备方法及含有这些化合物的药物组合物
EA200100108A1 (ru)	2001-12-24	Применение биогенных сульфаматов эстрогенов для гормонзаместительной терапии
YU57201A (sh)	2005-06-10	16-hidroksiestratrieni kao selektivno aktivni estrogeni
AU4246501A (en)	2001-09-24	4-fluoroalkyl-2h-benzopyrans with anti-estrogenic activity
JP2005532350A (ja)	2005-10-27	新しいエトノゲストレルエステル
ES2300431T3 (es)	2008-06-16	Esteroides androgenos halogenados en posicion 11 y sustituidos en posicion 7.
DK1226155T3 (da)	2007-09-10	18-nor-steroider som selektivt virksomme östrogener
CU23414B7 (es)	2009-09-08	Estratrienos 9-alfa-sustituidos como estrógenos de eficacia selectiva
YU77302A (sh)	2005-11-28	8beta-hidrokarbil-supstituisani estratrieni kao selektivno delotvorni estrogeni
HU230920B1 (hu)	2019-03-28	Depresszió kezelésére szolgáló androgén gyógyászati készítmények
TN2010000007A1 (en)	2011-09-26	8-beta- substituted estratrienes as selectively active estrogens
KR100200462B1 (ko)	1999-06-15	아로마타제 억제제로서 유용한 2베타, 19-메틸렌아미노 다리 걸친 스테로이드
ES2260294T3 (es)	2006-11-01	17-metilen-esteroides halogenados en posicion 4, procedimientos para su preparacion y composiciones que contienen estos compuestos.
UY26967A1 (es)	2003-04-30	Derivados 8beta-sustituidos de 11beta-pentil y 11beta-hexil-estra-1,3,5(10)-trieno.-
RU2006126632A (ru)	2008-01-27	Стероиды, имеющие смешанный андрогенный и прогрестагенный профиль